SecBot SecBot
Biotech Drug Report Generated Jul 6, 2026

Praluent

REGN·REGENERON PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and marketed since July 2015
Why 4/10
Praluent is already FDA-approved and marketed with no pending PDUFA date or pivotal readout scheduled in the next ~12 months. The last major label expansion (pediatric HeFH) was in March 2024, and the Amgen patent litigation was settled in March 2026. ImpactScore is capped at 4 under the rubric: approved drug with no imminent binary catalyst, and a small contributor (under 1%) to Regeneron's ~$14.3B annual revenue.
Actionable Insight NEUTRAL

Praluent is a mature, marketed product that is unlikely to drive material share-price moves for REGN on its own. Investors should instead focus on Regeneron's much larger value drivers: Dupixent (the biggest growth engine), EYLEA HD (eye disease), and the broader pipeline. The key risk to watch for Praluent specifically is biosimilar entry as key patents expire, but even disruption there would be a rounding error for REGN's top line.

Price Chart

Loading chart...

Executive Summary

Praluent (generic: alirocumab) is an injectable PCSK9 inhibitor cholesterol drug co-developed by Regeneron (NASDAQ: REGN) and Sanofi (SNY). It was the first PCSK9 inhibitor approved in the US (July 2015) and now carries indications for cardiovascular risk reduction, primary hyperlipidemia (including heterozygous and homozygous familial hypercholesterolemia), and pediatric HeFH (ages 8+). Despite being a first-in-class drug, Praluent is a distant #2 behind Amgen's Repatha, which commands about twice the prescription volume. For Regeneron, Praluent is a minor revenue contributor, US net product sales of roughly $57M-$72M per quarter, representing well under 1% of the company's $14.3B in 2025 total revenue. With no imminent regulatory catalysts and looming biosimilar competition as patents expire, Praluent is a low-impact asset for REGN shareholders.

How It Works

Praluent is a monoclonal antibody (a lab-made immune protein) that blocks a specific enzyme called PCSK9. Normally, PCSK9 destroys the "docking stations" on liver cells that remove bad cholesterol (LDL) from the bloodstream. By blocking PCSK9, Praluent preserves more docking stations, allowing the liver to clear more LDL cholesterol out of the blood, lowering cholesterol levels and reducing the risk of heart attacks and strokes.

Trial Status

Praluent has been FDA-approved since July 2015. The label has been expanded multiple times since: in 2019 to include cardiovascular outcomes (heart attack/stroke risk reduction), in 2021 for homozygous familial hypercholesterolemia (HoFH), and in March 2024 for pediatric patients aged 8+ with heterozygous familial hypercholesterolemia (HeFH). No further pivotal trials or regulatory decisions are pending.

The Two-Sided Case

▲ Bull Case5
Praluent is a commercially established, approved drug with a growing label, the March 2024 pediatric HeFH expansion opened a new patient population (source: Regeneron press release via investor.regeneron.com)
The global revenue trajectory is positive: Pharmacompass estimates 2025 global sales of ~$624M, up ~20% from ~$501M in 2024 (source: pharmacompass.com)
The long-running Amgen patent dispute was settled in March 2026, removing a major overhang and litigation uncertainty (source: juve-patent.com)
Praluent contributes to Regeneron's Sanofi collaboration revenue stream, which totaled $5.242B in 2025 across all partnered antibodies (source: Regeneron Q4/FY2025 earnings press release)
Analyst consensus on REGN remains bullish (27 buy/overweight ratings vs 11 hold, 0 sell) with a mean price target of $833, implying ~27% upside from ~$654
▼ Bear Case5
Praluent is a minor product for Regeneron, US Q1 2026 net sales of ~$56.8M represent well under 1% of the company's $14.3B total 2025 revenue, making it nearly irrelevant to the investment thesis (source: finviz.com, Regeneron FY2025 earnings)
Praluent is the #2 PCSK9 player with roughly half the prescription volume of Amgen's Repatha (~7K vs ~14K weekly Rx), indicating persistent market share disadvantage (source: biopharmadive.com citing IQVIA data)
Key US patents are reportedly expiring around 2025, opening the door to biosimilar competition that could erode pricing and sales (source: drugpatentwatch.com)
A German court blocked Praluent sales for patent infringement, showing the patent/IP risk is global, not just US-centric (source: insights.citeline.com)
Several analysts recently downgraded or reduced price targets on REGN in May 2026, with Citigroup cutting from Buy to Neutral and Leerink from Outperform to Market Perform, though these actions likely reflect broader REGN concerns beyond Praluent

Upcoming Catalysts

  • No near-term binary catalysts for Praluent specifically, drug is already fully approved and marketed
  • Biosimilar entry timelines as patents expire (first US patent expirations reportedly around 2025)
  • Quarterly earnings disclosures, Praluent US sales are reported as a line item in Regeneron's quarterly earnings (next: Q2 2026 results)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report

Sources · 11

Hover a chip for the title
1 en.wikipedia.org2 investor.regeneron.com3 pharmacompass.com4 investor.regeneron.com5 biopharmadive.com6 juve-patent.com7 finviz.com8 insights.citeline.com9 drugpatentwatch.com10 finviz.com11 investor.regeneron.com